Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $20.71 USD
Change Today -0.25 / -1.19%
Volume 724.6K
QDEL On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

12544 High Bluff Drive

Suite 200

San Diego, CA 92130

United States

Phone: 858-552-1100

Fax: 858-453-4338

Quidel Corporation engages in the development, manufacture, and marketing of rapid diagnostic testing solutions. The company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. Products The company provides diagnostic testing solutions under various brand names, including among others, the following: Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain. System Platforms—New and In Development: The company’s diagnostic testing solutions are provided through various proprietary platforms, including the following platforms: Fluorescent Immunoassays Sofia Analyzer: Sofia is the brand name for the company’s next generation fluorescent immunoassay (FIA) system. The easy-to-use Sofia Analyzer combines software, when used in conjunction with Sofia FIA tests, to yield an automatic, objective result that is readily available on the instrument’s screen, in a hard-copy printout, and in a transmissible electronic form that can network via a lab information system to hospital and medical center databases. The Sofia Analyzer provides for different operational modes to accommodate both small and large laboratories, as well as other features designed to facilitate use in various healthcare settings, including hospitals, medical centers, and small clinics. Molecular Assays Lyra: The company’s open system molecular assays run on thermocyclers on the market. The company has existing Lyra Molecular Real-Time Polymerase Chain Reaction (PCR) assays that provide room temperature storage and ready-to-use reagent configurations. Amplivue: With its Molecular Amplivue hand-held molecular diagnostic assay platform, the detection of the pathogen is achieved using a hand-held, fully contained cassette that combines isothermal Helicase Dependent Amplification (HDA) with lateral flow detection technology. Molecular Systems in Development Savanna: The company is in the process of developing the Savanna system as a rugged, fully-integrated system with novel extraction, and sample in/result out simplicity. Solana: The company is in the process of developing the Solana system as an extension to the Amplivue product line, running the same proprietary Helicase Dependent Amplification technology. Medical and Wellness Categories The company’s products address the following medical and wellness categories: Infectious Diseases Influenza: The company’s Sofia Influenza A+B test, used in conjunction with its Sofia Analyzer, and its QuickVue influenza tests are rapid, qualitative tests for the detection of the viral antigens of influenza type A and B, the two most common types of the influenza virus. In addition, its Sofia Influenza A+B test has special 510(k) clearance for an update to its package insert to include analytical reactivity with an avian Influenza A (H7N9) strain, A/Anhui/1/2013. In addition, during 2013, the company began selling its Quidel Molecular Influenza A+B assay for use on the QuantStudio Dx Real-Time PCR Instruments by Life Technologies. Streptococci: The company’s Sofia Strep A fluorescent immunoassay, used in conjunction with its Sofia Analyzer, and its QuickVue Strep A tests are intended for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs or confirmation of presumptive Group A Streptococcal colonies recovered from culture. Also, in 2013, the company began selling its AmpliVue Group B Strep Assay. In 2014, the company began selling its AmpliVue Group A Strep Assays. In 2014, the company also received the U.S. Food and Drug Administration (FDA) clearance, via the de novo request procedure, for its Lyra Direct Strep Assay, a multiplex real-time PCR assay that detects and differentiates between pyogenic Group A and pyogenic C or G Streptococcal throat infections. Respiratory Syncytial Virus (RSV) Test: The company’s Sofia RSV test and its QuickVue RSV test are rapid immunoassay tests for RSV. Multiplex Respiratory: The company’s cell culture and direct fluorescent assays (DFA) detection sol

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $20.71 USD -0.25

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $8.50 USD +0.02
Luminex Corp $17.23 USD +0.18
Meridian Bioscience Inc $18.09 USD -0.09
OraSure Technologies Inc $4.94 USD -0.12
T2 Biosystems Inc $14.41 USD +0.13
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 134.2x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.